General considerations of model-based meta-analysis
10.12092/j.issn.1009-2501.2020.11.006
- Author:
Lujin LI
;
Junjie DING
;
Dongyang LIU
;
Xipei WANG
;
Chenhui DENG
;
Shangmin JI
;
Wenjun CHEN
;
Guangli MA
;
Kun WANG
;
Yucheng SHENG
;
Ling XU
;
Qi PEI
;
Yuancheng CHEN
;
Rui CHEN
;
Jun SHI
;
Gailing LI
;
Yaning WANG
;
Yuzhu WANG
;
Haitang XIE
;
Tianyan ZHOU
;
Yi FANG
;
Jing ZHANG
;
Zheng JIAO
;
Bei HU
;
Qingshan ZHENG
- Publication Type:Journal Article
- Keywords:
Cost-effectiveness analysis;
Drug development;
Expert consensus;
Model-based meta-analysis;
Rational use of medicines
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(11):1250-1267
- CountryChina
- Language:Chinese
-
Abstract:
With the increasing cost of drug development and clinical trials, it is of great value to make full use of all kinds of data to improve the efficiency of drug development and to provide valid information for medication guidelines. Model-based meta-analysis (MBMA) combines mathematical models with meta-analysis to integrate information from multiple sources (preclinical and clinical data, etc.) and multiple dimensions (targets/mechanisms, pharmacokinetics/pharmacodynamics, diseases/indications, populations, regimens, biomarkers/efficacy/safety, etc.), which not only provides decision-making for all key points of drug development, but also provides effective information for rational drug use and cost-effectiveness analysis. The classical meta-analysis requires high homogeneity of the data, while MBMA can combine and analyze the heterogeneous data of different doses, different time courses, and different populations through modeling, so as to quantify the dose-effect relationship, time-effect relationship, and the relevant impact factors, and thus the efficacy or safety features at the level of dose, time and covariable that have not been involved in previous studies. Although the modeling and simulation methods of MBMA are similar to population pharmacokinetics/pharmacodynamics (Pop PK/PD), compared with Pop PK/PD, the advantage of MBMA is that it can make full use of literature data, which not only improves the strength of evidence, but also can answer the questions that have not been proved or can not be answered by a single study. At present, MBMA has become one of the important methods in the strategy of model-informed drug development (MIDD). This paper will focus on the application value, data analysis plan, data acquisition and processing, data analysis and reporting of MBMA, in order to provide reference for the application of MBMA in drug development and clinical practice.
